How Cosentyx Impacts Immune Systems in Older Adults
Cosentyx (secukinumab) works by targeting interleukin-17A (IL-17A), a cytokine involved in inflammatory processes. By blocking IL-17A, Cosentyx reduces inflammation associated with certain autoimmune conditions [1].
In elderly patients, as in other age groups, this mechanism can increase susceptibility to infections [2]. The immune system naturally undergoes changes with aging, a process known as immunosenescence, which can affect its ability to respond effectively to both pathogens and vaccines [3]. The impact of immunosuppressive therapies like Cosentyx on an already aging immune system is a consideration for healthcare providers [2].
What Infections Are More Likely with Cosentyx?
Patients taking Cosentyx may experience an increased risk of certain infections. These can include upper respiratory tract infections, such as nasopharyngitis, and fungal infections like candidiasis [2]. Serious infections have also been reported, necessitating careful monitoring of patients for any signs of new or worsening infections [1].
How Does Age Affect Cosentyx Safety?
Elderly patients may be more vulnerable to the adverse effects of medications due to physiological changes associated with aging, such as reduced kidney or liver function, or the presence of multiple comorbidities [3]. While clinical trials for Cosentyx have included older adults, specific data on the safety profile in this demographic, particularly regarding infection risk compared to younger patients, is continuously evaluated [2].
Are There Alternatives to Cosentyx for Elderly Patients?
Treatment decisions for elderly patients are individualized and consider the patient's overall health, other medications, and the specific condition being treated [3]. For conditions treated by Cosentyx, other biologic agents or non-biologic therapies may be available, each with their own efficacy and safety profiles [2].
When Did Cosentyx Become Available and What About Its Patents?
Cosentyx was approved by the U.S. Food and Drug Administration (FDA) in January 2015 [1]. Information regarding the patent status and exclusivity periods for Cosentyx can be found on specialized databases [4]. DrugPatentWatch.com tracks patent information for pharmaceuticals, including expiration dates and any related litigation [4].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125502s161,125503s056lbl.pdf
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399347/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487752/
4. https://drugpatentwatch.com/